Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Chiasma's share price for the quarter that ended in Mar. 2021 was $3.13. Chiasma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2021 was 57.84 Mil. Therefore, Chiasma's market cap for the quarter that ended in Mar. 2021 was $181.05 Mil.
Chiasma's quarterly market cap
increased
from Sep. 2020 ($248.56 Mil) to Dec. 2020 ($251.50 Mil) but then
declined
from Dec. 2020 ($251.50 Mil) to Mar. 2021 ($181.05 Mil).
Chiasma's annual market cap
increased
from Dec. 2018 ($76.06 Mil) to Dec. 2019 ($208.71 Mil) and
increased
from Dec. 2019 ($208.71 Mil) to Dec. 2020 ($251.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chiasma's Enterprise Value for Today is $122.78 Mil.
Chiasma Market Cap Historical Data
The historical data trend for Chiasma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Chiasma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiasma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiasma's Market Cap distribution charts can be found below:
* The bar in red indicates where Chiasma's Market Cap falls into.
Chiasma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Chiasma's Market Cap for the fiscal year that ended in Dec. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiasma (NAS:CHMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Chiasma Market Cap Related Terms
Thank you for viewing the detailed overview of Chiasma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHMA has been successfully added to your 